Add to ORKGAround 75% of breast tumours express estrogen receptor (ER+). Endocrine therapy (ET) is a cornerstone in the treatment of both early and metastatic disease, but its effectiveness is limited by the developing of acquired resistance and more rarely by de novo resistance. Understanding the mechanisms of resistance to ET represents a challenge. Recently acquired mutations in ESR1, have been associated with resistance to aromatase inhibitor (Ai) therapy in hormone-refractory metastatic breast cancer (MBC)
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Abstract Endocrine therapy is the mainstay of treatment in estrogen receptor-positive ...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquire...
AbstractMutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Abstract In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
The majority of breast cancer cases are dependent on estrogen signaling, which is why endocrine ther...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Abstract Endocrine therapy is the mainstay of treatment in estrogen receptor-positive ...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are, therefore, trea...
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquire...
AbstractMutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number o...
Abstract In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
The majority of breast cancer cases are dependent on estrogen signaling, which is why endocrine ther...
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although ...
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Abstract Endocrine therapy is the mainstay of treatment in estrogen receptor-positive ...